# A Real-world Study of Durvalumab for Lung Cancer in China

> **NCT04672759** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Stage III
- Small-Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04672759
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-28
- **Primary completion:** 2021-06
- **Final completion:** 2024-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672759, "A Real-world Study of Durvalumab for Lung Cancer in China". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04672759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*